News

News Subscription

Dec 10. 2018
Basilea Pharmaceutica AG : Continued strong Cresemba® (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea
Read more
Download
Nov 14. 2018
Basilea presents preclinical data on its anticancer drug candidate BAL101553 at EORTC-NCI-AACR symposium
Read more
Download
Aug 14. 2018
Basilea reports half-year financial results reflecting strong in-market product sales growth in addition to progress and expansion of the R&D pipeline
Read more
Download
Aug 13. 2018
Basilea reports on first Cresemba® approval in MENA region
Read more
Download
Aug 09. 2018
Basilea starts clinical phase 3 study with antibiotic ceftobiprole in Staphylococcus aureus bacteremia (SAB)
Read more
Download
Jul 19. 2018
Basilea reports receipt of milestone payment based on first Cresemba® approval in Latin America
Read more
Download
Jun 26. 2018
Basilea starts clinical phase 2a expansion with BAL101553 in ovarian cancer and glioblastoma
Read more
Download
Jun 05. 2018
Basilea reports presentation of phase 1 clinical data with anticancer drug candidate BAL101553 at ASCO meeting
Read more
Download
May 24. 2018
Basilea Pharmaceutica: Subscription to Basilea's Press Release Newsletter
Read more
May 15. 2018
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Saudi Arabia by Hikma Pharmaceuticals LLC
Read more
Download